NEW YORK (GenomeWeb News) - Mosaic Health Care Consultants has agreed to develop reimbursement strategies and programs for Ciphergen Biosystems' ovarian cancer test, Ciphergen said yesterday. 
Ciphergen's ovarian cancer triage test, which the company plans to submit for FDA approval after it completes clinical trials, uses a biomarker panel to measure risk stratification.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.